This Review summarizes the current knowledge on mortality-defining toxicities of chimeric antigen receptor T cell therapies beyond cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome. The authors discuss underlying mechanisms and how these affect timing and management, and outline key unmet needs and future priorities.